TON - January/February 2014 Vol 7 No 1

About 7500 participants from more than 90 countries attended the breast cancer symposium. The following are selected brief highlights from these meetings. Read More ›

Clinical trials are a vital component of the continued search for safe and effective treatments. Along with the researchers, the patients and healthy volunteers who participate in testing devices, diagnostic procedures, new drugs, and new uses for established therapies contribute to the advancement of knowledge and patient care. Read More ›


Hair loss was one of the biggest emotional struggles I faced as a young woman with cancer. When I think back about losing my hair to chemo almost 10 years ago, I am struck by how both the cultural norms and headwear options have changed since then. Read More ›

Via Christi is the largest provider of healthcare services in Kansas, with its doctors, hospitals, senior villages, and other medical services. Read More ›

Clinicians want to provide excellent patient care without having to appraise every new study in their field, but producing the “authoritative, instructive resource for most clinical scenarios” is not as straightforward as it would seem, according to David Garcia, MD, Professor of Medicine at the University of Washington in Seattle. Read More ›

Balancing work and home life is difficult, especially when you work in oncology. Read More ›

The keynote address of the Fourth Annual Conference of the Academy of Oncology Nurse & Patient Navigators (AONN+) was delivered by Linda W. Ferris, PhD. Ferris is vice president, Oncology System Service Line, at Centura Health in Colorado and Kansas, as well as chair of the Commission on Cancer (CoC) Accreditation Committee. Read More ›

Of all newly diagnosed breast cancer, 6% to 10% is metastatic, and a proportion of women with early breast cancer eventually develop metastasis. Treatment of metastatic breast cancer has improved considerably, and patients are living longer with metastatic disease. Read More ›

For patients with non-Hodgkin lymphoma (NHL) receiving chemotherapy, primary prophylaxis against febrile neutropenia (FN) can safely be administered on the same treatment day, if necessary, according to a review of patients from the Cleveland Clinic, presented at the 2013 American Society of Hematology annual meeting. Read More ›

Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: